Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 ...

In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic stocks. In contrast to drugs like cocaine or marijuana, psychedelics ...

LONDON & NEW YORK, March 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the ...

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Seven ...

Ladies and gentlemen, thank you for standing by, and welcome to the COMPASS Pathways Limited fourth quarter 2024 investor call. [Operator instructions] I will now hand today's call over to Steve ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...